Forecast Of The Day: Boston Scientific’s Interventional Cardiology Revenues

+36.45%
Upside
37.37
Market
50.99
Trefis
BSX: Boston Scientific logo
BSX
Boston Scientific

What?

Trefis expects revenue from Boston Scientific’s (NYSE: BSX) Interventional Cardiology business – which sells products such as stents and catheters – to grow from around $2.3 billion in 2020 to about $2.7 billion in 2021 and over $2.8 billion in 2022.

Why?

Relevant Articles
  1. What’s Happening With Boston Scientific Stock?
  2. What To Expect From Boston Scientific Stock Following Q1 Earnings?
  3. This Software Company Is Likely To Offer Better Returns Over Boston Scientific Stock
  4. Company Of The Day: Boston Scientific
  5. Is Boston Scientific Stock A Good Buy At $43?
  6. What To Expect From Boston Scientific Stock Following Q4 Earnings?

Although revenue dipped in 2020, due to the Covid-19 pandemic, we expect sales to rebound in 2021 as the number of elective surgeries and cardiac procedures increases post the lockdowns.

So What?

The re-opening of the economy and strong vaccination rates in the U.S. should bode well for Boston Scientific’s medical devices and consumables sales across its operating segments. We value BSX stock at $49 per share, about 15% ahead of the current market price.

See Our Complete Analysis For Boston Scientific

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market since 2016

See all Trefis Price Estimates and Download Trefis Data here

What’s behind Trefis? See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams